Anti-Infective Therapy

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 263808 Experts worldwide ranked by ideXlab platform

M. S. Elisaf - One of the best experts on this subject based on the ideXlab platform.

  • Lysis syndrome during Therapy of visceral leishmaniasis
    Infection, 2012
    Co-Authors: E. N. Liberopoulos, A. A. Kei, M. S. Elisaf
    Abstract:

    Introduction Lysis syndrome is a constellation of metabolic disorders usually seen after the initiation of chemoTherapy for rapidly proliferating malignancies (tumor lysis syndrome). Reported herein is a tumor lysis-like syndrome after the initiation of Anti-Infective Therapy for visceral leishmaniasis. Patients and methods Ten consecutive patients with visceral leishmaniasis were administered liposomal amphotericin B. Levels of serum uric acid, phosphate, creatinine, blood urea nitrogen, potassium, calcium, and magnesium were evaluated prior to as well as 4 and 30 days following the initiation of treatment. Results During the 4th post-treatment day significant increases in the levels of serum uric acid, phosphate, creatinine, and blood urea nitrogen were seen, while the levels of calcium, potassium, and magnesium were not significantly altered. Patients were treated by hydration, urine alkalization, and administration of allopurinol as needed. A recovery of metabolic abnormalities was recorded 1 month later, although some patients had evidence of residual injury. Conclusion A lysis syndrome may complicate the treatment of visceral leishmaniasis. Awareness of this complication can lead to the initiation of prophylactic treatment as well as to early recognition and management of this syndrome in susceptible patients.

  • Lysis syndrome during Therapy of visceral leishmaniasis.
    Infection, 2011
    Co-Authors: E. N. Liberopoulos, A. A. Kei, M. S. Elisaf
    Abstract:

    Introduction Lysis syndrome is a constellation of metabolic disorders usually seen after the initiation of chemoTherapy for rapidly proliferating malignancies (tumor lysis syndrome). Reported herein is a tumor lysis-like syndrome after the initiation of Anti-Infective Therapy for visceral leishmaniasis.

James A Hoch - One of the best experts on this subject based on the ideXlab platform.

  • a two component signal transduction system essential for growth of bacillus subtilis implications for anti infective Therapy
    Journal of Bacteriology, 1998
    Co-Authors: Celine Fabret, James A Hoch
    Abstract:

    A two-component signal transduction system encoded by the yycF and yycG genes is part of an operon containing three genes, yycH, yycI, and yycJ, with no known function and a gene, yycK, coding for an HtrA-like protease. This operon was transcribed during growth, and its transcription shut down as the cells approached stationary phase. This decreased transcription was not Spo0A dependent. The HtrA protease gene was separately controlled during sporulation from a ςG promoter. Studies using insertional inactivation plasmids revealed that neither yycF nor yycG could be inactivated, whereas the other genes were inactivated without loss of viability. A temperature-sensitive YycF response regulator mutant was isolated and shown to have an H215P mutation in a putative DNA-binding domain which is closely related to the OmpR family of response regulators. At the nonpermissive temperature, cultures of the mutant strain stopped growth within 30 min, and this was followed by a decrease in optical density. Microscopically, many of the cells appeared to retain their structure while being empty of their contents. The essential processes regulated by this two-component system remain unknown. A search of the genome databases revealed YycF, YycG, and YycJ homologues encoded by three linked genes in Streptococcus pyogenes. The high level of identity of these proteins (71% for YycF) suggests that this system may play a similar role in gram-positive pathogens.

  • two component signal transduction as a target for microbial anti infective Therapy
    Antimicrobial Agents and Chemotherapy, 1998
    Co-Authors: John F Barrett, James A Hoch
    Abstract:

    Bacteria are continually bombarded by a multitude of chemicals from their environment, some of which may serve as potential sources of carbon, nitrogen, and energy, while others may act as poisons of their metabolic and regulatory processes. This mix of environmental signals and insults is highly variable and most certainly locale dependent. The potential for an organism to grow and divide within any locale or ecological niche is determined genetically by its repertoire of genes and by its capacity to induce new gene expression to cope with new environments. Often a bacterial infection results from an organism moving from an environment where its presence is benign (e.g., the gastrointestinal system) to another environment where it poses a serious problem (e.g., the urinary tract). This movement between ecological niches requires that the organism “sense” its presence in the new environment and “respond” by expressing new genetic information to permit it to occupy and grow within it. Success in this endeavor is the result of the sum of incremental genetic responses to the new environment of the host.

E. N. Liberopoulos - One of the best experts on this subject based on the ideXlab platform.

  • Lysis syndrome during Therapy of visceral leishmaniasis
    Infection, 2012
    Co-Authors: E. N. Liberopoulos, A. A. Kei, M. S. Elisaf
    Abstract:

    Introduction Lysis syndrome is a constellation of metabolic disorders usually seen after the initiation of chemoTherapy for rapidly proliferating malignancies (tumor lysis syndrome). Reported herein is a tumor lysis-like syndrome after the initiation of Anti-Infective Therapy for visceral leishmaniasis. Patients and methods Ten consecutive patients with visceral leishmaniasis were administered liposomal amphotericin B. Levels of serum uric acid, phosphate, creatinine, blood urea nitrogen, potassium, calcium, and magnesium were evaluated prior to as well as 4 and 30 days following the initiation of treatment. Results During the 4th post-treatment day significant increases in the levels of serum uric acid, phosphate, creatinine, and blood urea nitrogen were seen, while the levels of calcium, potassium, and magnesium were not significantly altered. Patients were treated by hydration, urine alkalization, and administration of allopurinol as needed. A recovery of metabolic abnormalities was recorded 1 month later, although some patients had evidence of residual injury. Conclusion A lysis syndrome may complicate the treatment of visceral leishmaniasis. Awareness of this complication can lead to the initiation of prophylactic treatment as well as to early recognition and management of this syndrome in susceptible patients.

  • Lysis syndrome during Therapy of visceral leishmaniasis.
    Infection, 2011
    Co-Authors: E. N. Liberopoulos, A. A. Kei, M. S. Elisaf
    Abstract:

    Introduction Lysis syndrome is a constellation of metabolic disorders usually seen after the initiation of chemoTherapy for rapidly proliferating malignancies (tumor lysis syndrome). Reported herein is a tumor lysis-like syndrome after the initiation of Anti-Infective Therapy for visceral leishmaniasis.

Giovanni E Salvi - One of the best experts on this subject based on the ideXlab platform.

  • Anti-Infective Therapy of peri-implant mucositis with adjunctive delivery of a sodium hypochlorite gel: a 6-month randomized triple-blind controlled clinical trial
    Clinical Oral Investigations, 2019
    Co-Authors: Vincenzo Iorio-siciliano, Anton Sculean, Giovanni E Salvi, Andrea Blasi, Stefan-ioan Stratul, Luca Ramaglia, Darian Rusu
    Abstract:

    Objective To evaluate the effects of adjunctive delivery of a sodium hypochlorite gel in the treatment of peri-implant mucositis (PM). Materials and methods Forty-six subjects with 68 implants diagnosed with PM were randomly assigned to two treatment groups. Prior to mechanical debridement, a sodium hypochlorite gel was delivered to the implants of the test group while implants of the control group received a placebo gel. Application of both test and placebo gels was repeated 5 times at baseline. The primary outcome variable was the change in pocket probing depth (PPD) between baseline and 6 months. Results After 6 months, the mean PPD decreased statistically significantly from 3.93 ± 1.09 mm to 3.04 ± 0.46 mm in the test ( p  = 0.0001) and from 3.68 ± 0.85 mm to 3.07 ± 0.58 mm in the control ( p  = 0.0001) group, respectively. No statistically significant difference ( p  = 0.53) was observed with respect to PPD changes from baseline to 6 months between test (0.88 ± 1.04 mm) and control group (0.61 ± 0.75 mm), respectively. The number of implants with bleeding on probing (BoP) decreased statistically significantly from 33 to 18 in the test group ( p  = 0.0001) and from 34 to 23 in the control group ( p  = 0.0001) after 6 months. Conclusions In conclusion and within the limits of the present study, changes in PPD from baseline to 6 months were not statistically significantly different between groups. Complete resolution of mucosal inflammation was not achieved with either of the therapies. Clinical relevance The present outcomes have showed that a complete resolution of peri-implant mucositis is not possible to obtain by means mechanical debridement with or without a sodium hypochlorite gel application.

  • anti infective Therapy of peri implantitis with adjunctive local drug delivery or photodynamic Therapy 12 month outcomes of a randomized controlled clinical trial
    Clinical Oral Implants Research, 2014
    Co-Authors: Mario Bassetti, Dorothee Schar, Christoph A Ramseier, Sigrun Eick, Nicole B Arweiler, Anton Sculean, Beat Wicki, Giovanni E Salvi
    Abstract:

    OBJECTIVE: The objective of the study is to compare the clinical, microbiological and host-derived effects in the non-surgical treatment of initial peri-implantitis with either adjunctive local drug delivery (LDD) or adjunctive photodynamic Therapy (PDT) after 12 months. MATERIALS AND METHODS: Forty subjects with initial peri-implantitis, that is, pocket probing depths (PPD) 4-6 mm with bleeding on probing (BoP) and radiographic bone loss ≤2 mm, were randomly assigned to two treatment groups. All implants were mechanically debrided with titanium curettes and with a glycine-based powder airpolishing system. Implants in the test group (N = 20) received adjunctive PDT, whereas minocycline microspheres were locally delivered into the peri-implant pockets of control implants (N = 20). At sites with residual BoP, treatment was repeated after 3, 6, 9 and 12 months. The primary outcome variable was the change in the number of peri-implant sites with BoP. Secondary outcome variables included changes in PPD, clinical attachment level (CAL), mucosal recession (REC) and in bacterial counts and crevicular fluid (CF) levels of host-derived biomarkers. RESULTS: After 12 months, the number of BoP-positive sites decreased statistically significantly (P   0.05) were observed between groups after 12 months with respect to clinical, microbiological and host-derived parameters. CONCLUSIONS: Non-surgical mechanical debridement with adjunctive PDT was equally effective in the reduction of mucosal inflammation as with adjunctive delivery of minocycline microspheres up to 12 months. Adjunctive PDT may represent an alternative approach to LDD in the non-surgical treatment of initial peri-implantitis.

  • anti infective Therapy of peri implantitis with adjunctive local drug delivery or photodynamic Therapy six month outcomes of a prospective randomized clinical trial
    Clinical Oral Implants Research, 2013
    Co-Authors: Dorothee Schar, Christoph A Ramseier, Sigrun Eick, Nicole B Arweiler, Anton Sculean, Giovanni E Salvi
    Abstract:

    To compare the adjunctive clinical effects in the non-surgical treatment of peri-implantitis with either local drug delivery (LDD) or photodynamic Therapy (PDT).

A. A. Kei - One of the best experts on this subject based on the ideXlab platform.

  • Lysis syndrome during Therapy of visceral leishmaniasis
    Infection, 2012
    Co-Authors: E. N. Liberopoulos, A. A. Kei, M. S. Elisaf
    Abstract:

    Introduction Lysis syndrome is a constellation of metabolic disorders usually seen after the initiation of chemoTherapy for rapidly proliferating malignancies (tumor lysis syndrome). Reported herein is a tumor lysis-like syndrome after the initiation of Anti-Infective Therapy for visceral leishmaniasis. Patients and methods Ten consecutive patients with visceral leishmaniasis were administered liposomal amphotericin B. Levels of serum uric acid, phosphate, creatinine, blood urea nitrogen, potassium, calcium, and magnesium were evaluated prior to as well as 4 and 30 days following the initiation of treatment. Results During the 4th post-treatment day significant increases in the levels of serum uric acid, phosphate, creatinine, and blood urea nitrogen were seen, while the levels of calcium, potassium, and magnesium were not significantly altered. Patients were treated by hydration, urine alkalization, and administration of allopurinol as needed. A recovery of metabolic abnormalities was recorded 1 month later, although some patients had evidence of residual injury. Conclusion A lysis syndrome may complicate the treatment of visceral leishmaniasis. Awareness of this complication can lead to the initiation of prophylactic treatment as well as to early recognition and management of this syndrome in susceptible patients.

  • Lysis syndrome during Therapy of visceral leishmaniasis.
    Infection, 2011
    Co-Authors: E. N. Liberopoulos, A. A. Kei, M. S. Elisaf
    Abstract:

    Introduction Lysis syndrome is a constellation of metabolic disorders usually seen after the initiation of chemoTherapy for rapidly proliferating malignancies (tumor lysis syndrome). Reported herein is a tumor lysis-like syndrome after the initiation of Anti-Infective Therapy for visceral leishmaniasis.